Boundless Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$63.6M | -$73.3M | -$54.8M |
| Operating expenses | $63.6M | $73.3M | $54.8M |
| Cash from operations | -$46.7M | -$60.8M | -$46.9M |
| Capital expenditure | $546,000 | $2.5M | $633,000 |
| Free cash flow | -$47.2M | -$63.4M | -$47.5M |
| Total assets | $157.1M | $206.4M | $129.9M |
| Total liabilities | $58.4M | $55.8M | $9.4M |
Shares outstanding 22.5M · Free float 71.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.